Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia
January 7, 2021
January 7, 2021
MedinCell announces the resume of listing of its shares on Euronext Paris as of the opening of the stock exchange tomorrow
January 7, 2021
January 7, 2021
Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin
December 17, 2020
December 17, 2020
Live webcast of the Shareholders’ Meeting on Tuesday, December 15, 2020
December 11, 2020
December 11, 2020
MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations
